Selected research
Industry Research
Fidaxomicin Industry Research Report 2026
Market perspective
The global Fidaxomicin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fidaxomicin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fidaxomicin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fidaxomicin include Merck, Livzon Group, Tecoland, Rochem, Optimer Pharmaceuticals, Olon, BrightGene Bio-Medical Technology and Astellas, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fidaxomicin market in terms of revenue (US$ million) and, where applicable, sales volume (W Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fidaxomicin Market by Company
Merck
Livzon Group
Tecoland
Rochem
Optimer Pharmaceuticals
Olon
BrightGene Bio-Medical Technology
Astellas
Fidaxomicin Segment by Type
Purity:90%
Purity:95%
Others
Fidaxomicin Segment by Application
Hospital
Retail Pharmacies
Fidaxomicin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fidaxomicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fidaxomicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fidaxomicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fidaxomicin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fidaxomicin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fidaxomicin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity:90%
- Purity:95%
- Others
Applications
- Hospital
- Retail Pharmacies
Companies covered
- Merck
- Livzon Group
- Tecoland
- Rochem
- Optimer Pharmaceuticals
- Olon
- BrightGene Bio-Medical Technology
- Astellas
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fidaxomicin Market Size (2021-2032)
- 2.2.2 Global Fidaxomicin Sales (2021-2032)
- 2.2.3 Global Fidaxomicin Market Average Price (2021-2032)
- 2.3 Fidaxomicin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity:90%
- 2.3.3 Purity:95%
- 2.3.4 Others
- 2.4 Fidaxomicin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fidaxomicin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fidaxomicin Sales (W Pcs) of Manufacturers (2021-2026)
- 3.3 Global Fidaxomicin Revenue of Manufacturers (2021-2026)
- 3.4 Global Fidaxomicin Average Price by Manufacturers (2021-2026)
- 3.5 Global Fidaxomicin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fidaxomicin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fidaxomicin, Product Type & Application
- 3.8 Global Manufacturers of Fidaxomicin, Established Date
- 3.9 Global Fidaxomicin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Fidaxomicin Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Livzon Group
- 4.2.1 Livzon Group Company Information
- 4.2.2 Livzon Group Business Overview
- 4.2.3 Livzon Group Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Livzon Group Fidaxomicin Product Portfolio
- 4.2.5 Livzon Group Recent Developments
- 4.3 Tecoland
- 4.3.1 Tecoland Company Information
- 4.3.2 Tecoland Business Overview
- 4.3.3 Tecoland Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Tecoland Fidaxomicin Product Portfolio
- 4.3.5 Tecoland Recent Developments
- 4.4 Rochem
- 4.4.1 Rochem Company Information
- 4.4.2 Rochem Business Overview
- 4.4.3 Rochem Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Rochem Fidaxomicin Product Portfolio
- 4.4.5 Rochem Recent Developments
- 4.5 Optimer Pharmaceuticals
- 4.5.1 Optimer Pharmaceuticals Company Information
- 4.5.2 Optimer Pharmaceuticals Business Overview
- 4.5.3 Optimer Pharmaceuticals Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Optimer Pharmaceuticals Fidaxomicin Product Portfolio
- 4.5.5 Optimer Pharmaceuticals Recent Developments
- 4.6 Olon
- 4.6.1 Olon Company Information
- 4.6.2 Olon Business Overview
- 4.6.3 Olon Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Olon Fidaxomicin Product Portfolio
- 4.6.5 Olon Recent Developments
- 4.7 BrightGene Bio-Medical Technology
- 4.7.1 BrightGene Bio-Medical Technology Company Information
- 4.7.2 BrightGene Bio-Medical Technology Business Overview
- 4.7.3 BrightGene Bio-Medical Technology Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio
- 4.7.5 BrightGene Bio-Medical Technology Recent Developments
- 4.8 Astellas
- 4.8.1 Astellas Company Information
- 4.8.2 Astellas Business Overview
- 4.8.3 Astellas Fidaxomicin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Astellas Fidaxomicin Product Portfolio
- 4.8.5 Astellas Recent Developments
5 Global Fidaxomicin Market Scenario by Region
- 5.1 Global Fidaxomicin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fidaxomicin Sales by Region: 2021-2032
- 5.2.1 Global Fidaxomicin Sales by Region: 2021-2026
- 5.2.2 Global Fidaxomicin Sales by Region: 2027-2032
- 5.3 Global Fidaxomicin Revenue by Region: 2021-2032
- 5.3.1 Global Fidaxomicin Revenue by Region: 2021-2026
- 5.3.2 Global Fidaxomicin Revenue by Region: 2027-2032
- 5.4 North America Fidaxomicin Market Facts & Figures by Country
- 5.4.1 North America Fidaxomicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fidaxomicin Sales by Country (2021-2032)
- 5.4.3 North America Fidaxomicin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Fidaxomicin Market Facts & Figures by Country
- 5.5.1 Europe Fidaxomicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fidaxomicin Sales by Country (2021-2032)
- 5.5.3 Europe Fidaxomicin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Fidaxomicin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fidaxomicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fidaxomicin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fidaxomicin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fidaxomicin Market Facts & Figures by Country
- 5.7.1 South America Fidaxomicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fidaxomicin Sales by Country (2021-2032)
- 5.7.3 South America Fidaxomicin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Fidaxomicin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fidaxomicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fidaxomicin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fidaxomicin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Fidaxomicin Sales by Type (2021-2032)
- 6.1.1 Global Fidaxomicin Sales by Type (2021-2032) & (W Pcs)
- 6.1.2 Global Fidaxomicin Sales Market Share by Type (2021-2032)
- 6.2 Global Fidaxomicin Revenue by Type (2021-2032)
- 6.2.1 Global Fidaxomicin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fidaxomicin Revenue Market Share by Type (2021-2032)
- 6.3 Global Fidaxomicin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fidaxomicin Sales by Application (2021-2032)
- 7.1.1 Global Fidaxomicin Sales by Application (2021-2032) & (W Pcs)
- 7.1.2 Global Fidaxomicin Sales Market Share by Application (2021-2032)
- 7.2 Global Fidaxomicin Revenue by Application (2021-2032)
- 7.2.1 Global Fidaxomicin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fidaxomicin Revenue Market Share by Application (2021-2032)
- 7.3 Global Fidaxomicin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fidaxomicin Value Chain Analysis
- 8.1.1 Fidaxomicin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fidaxomicin Production Mode & Process
- 8.2 Fidaxomicin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fidaxomicin Distributors
- 8.2.3 Fidaxomicin Customers
9 Global Fidaxomicin Analyzing Market Dynamics
- 9.1 Fidaxomicin Industry Trends
- 9.2 Fidaxomicin Industry Drivers
- 9.3 Fidaxomicin Industry Opportunities and Challenges
- 9.4 Fidaxomicin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst